Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+urothelial cancer patients (pts).

被引：14

作者：

Bajorin, Dean F.

Sharma, Padmanee

Quinn, David I.

Plimack, Elizabeth R.

Hoffman-Censits, Jean H.

O'Donnell, Peter H.

Siefker-Radtke, Arlene O.

Sheikh, Nadeem Anwar

Lill, Jennifer Susan

Trager, James B.

Gomella, Leonard G.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[6] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA

[7] Dendreon Pharmaceut Inc, Seattle, WA USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.4513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4513

引用

页数：2